Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2442-2447

  Vigano, Antonio ^a,d   Trutschnigg, Barbara ^a   Kilgour, Robert D ^a,b   Hamel, Nancy ^a   Hornby, Laura ^a   Lucar, Enriqueta ^a   Foulkes, William ^a   Tremblay, Michel L ^c   Morais, José A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Civil and Environmental Engineering   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SERUM ALBUMIN;

ACE GENE; ADULT; ADVANCED CANCER; AGE; ALLELE; ARTICLE; BLOOD CELL COUNT; BODY COMPOSITION; BODY FAT; BODY MASS; CANCER PATIENT; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DUAL ENERGY X RAY ABSORPTIOMETRY; DYNAMOMETRY; FEMALE; FUNCTIONAL STATUS; GENDER; GENE; GENETIC POLYMORPHISM; GRIP STRENGTH; HUMAN; LEAN BODY WEIGHT; LEUKOCYTE DIFFERENTIAL COUNT; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NUTRITIONAL STATUS; PRIORITY JOURNAL; SURVIVAL;

ABSORPTIOMETRY, PHOTON; AGED; ANIMALS; BODY COMPOSITION; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GASTROINTESTINAL NEOPLASMS; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUSCLE STRENGTH; NEOPLASMS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 65249168105     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1720     Document Type: Article

References (30)

1. Hopkinson NS, Nickol AH, Payne J, et al. Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:395-9.
2. Morley JE, Haren MT. Sarcopenia and Cachexia. In: Morley JE, Thomas DR, editors. Geriatric Nutrition. CRC Press (Taylor & Francis Group);2007. p.59-68.
3. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
4. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-8.
5. Montgomery H. Human gene for physical performance. Nature1998;393:221 -2.
6. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulinlike growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97:2509-16.
7. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001;142:1489-96.
8. Cassis L, Helton M, English V, Burke G. Angiotensin II regulates oxygen consumption. Am J Physiol Regul IntegrComp Physiol 2002;282:R445-53.
9. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008;31:492-501.
10. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition1996;12:S15-9.
11. 11.Taylor DH, Jr., OstbyeT. The effect of middle- and old-age body mass index on short-term mortality in older people. J Am Geriatr Soc 2001;49:1319-26.
12. Innes E. Handgrip strength testing: a review of the literature. Aust Occup Ther J 1999;46:120-40.
13. Cheon KT, Choi KH, Lee HB, Park SK, RheeYK, Lee YC. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 2000;178:351 -60.
14. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem1979;95:540.
15. Kritchevsky SB, Nicklas BJ,Visser M, et al. Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA 2005; 294:691 -8.
16. KatsuyaT, Horiuchi M, ChenYD, et al. Relations between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia, and dyslipidemia. Arterioscler Thromb Vasc Biol 1995;15:779-82.
17. 17. Montgomery H, Clarkson P, Barnard M, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 1999;353:541 -5.
18. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995;44:267-72.
19. 19. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: arandomized controlled trial. CMAJ 2007;9;177:867-74.
20. Trutschnigg B, Kilgour RD, Reinglas J, et al. Precision and reliability of strength (Jamar vs. Biodex handgrip) and body composition (dual-energy X-ray absorptiometry vs. bioimpedance analysis) measurements in advanced cancer patients. Appl Physiol Nutr Metab 2008;33:232-9.
21. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res2006;98:1123-33.
22. Coyle EF, Sidossis LS, HorowitzJF, Beltz JD. Cycling efficiency is related to the percentage of type I muscle fibers. Med Sci Sports Exerc 1992;24:782-8.
23. Yaren A, Oztop I,Turgut S,Turgut G, Degirmencioglu S, Demirpence M. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008;233:32-7.
24. Mrug M, StopkaT, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997;100:2310-4.
25. Rodgers KE, Xiong S, Steer R, DiZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000;18:287-94.
26. Vasku A, Soucek M, Znojil V, et al. Does angiotensin I converting enzyme inhibitor therapy have an antiproliferative effect on blood-forming bone marrow? Exp Hematol 1998;26:277-9.
27. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist,in rats. Eur J Pharmacol 1998;354:179-87.
28. Varagunam M, McCloskeyDJ, Sinnott PJ, Raftery MJ,Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int 2003;23:111 -5.
29. Girndt M, Heine GH, Kohler H. Gene polymorphism association studiesin dialysis: anemia and host immunity. Semin Dial 2006;19:227-31.
30. RantanenT, Era P, Kauppinen M, Heikkinen E. Maximal isometric muscle strength and socio-economic status, health, and physical activityin 75-year-old per-sons. J Aging Phys Act 1994;2:206-20.